✦ LIBER ✦

Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors

✍ Scribed by Shaoguang Li; Dongguang Li

Book ID: 114778296
Publisher: Carol Davila University of Medicine Bucharest, Romania
Year: 2007
Tongue: English
Weight: 295 KB
Volume: 11
Category: Article
ISSN: 1582-1838
DOI: 10.1111/j.1582-4934.2007.00108.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mechanisms of resistance to BCR-ABL and

Mechanisms of resistance to BCR-ABL and other kinase inhibitors

✍ Lamontanara, Allan Joaquim; Gencer, Emel Basak; Kuzyk, Orest; Hantschel, Oliver 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 523 KB

Bcr-Abl-mediated resistance to apoptosis

Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity

✍ Bueno-da-Silva, A E B; Brumatti, G; Russo, F O; Green, D R; Amarante-Mendes, G P 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 172 KB

Bcr – Abl-mediated resistance to apoptos

Bcr – Abl-mediated resistance to apoptosis is independent of PI 3-kinase activity

✍ Nishioka, Walter K; Mustelin, Tomas; Green, Douglas R; Amarante-Mendes, Gustavo 📂 Article 📅 1997 🏛 Nature Publishing Group 🌐 English ⚖ 291 KB

Stem cell transplantation for patients w

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I

✍ Nikolai Velev; Jorge Cortes; Richard Champlin; Dan Jones; Gabriela Rondon; Sergi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 1 views

Activity of histone deacetylase inhibito

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

✍ Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, Shinya Kimura… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 343 KB

Dynamic change of T315I BCR-ABL kinase d

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors

✍ Wan-Seok Kim; Dongho Kim; Dong-Wook Kim; Il-Young Kweon; Soo-Hyun Kim; Hyun-Gyun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB 👁 1 views

## Abstract We analysed the dynamic change of imatinib‐resistant mutations in BCR‐ABL kinase domain focusing on T315I mutation during dasatinib or nilotinib therapy. Fifty‐five imatinib‐resistant chronic myeloid leukaemia patients (32 patients with imatinib‐resistant mutations and 23 patients witho